About 18-19 coronavirus vaccine candidates are in different clinical trial stages and may be available in the coming months, Health Minister Harsh Vardhan said on Monday.
Maharashtra govt, California-based Zipline to launch the automated delivery service funded by Serum Institute.
This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das
British nationals arriving in India, irrespective of their vaccination status, will have to undergo 10 days of mandatory quarantine from October 4 as part of the reciprocal actions initiated by the government following the vaccine certification row between the two countries.
Vaccinating all citizens above the age of 18 years against COVID-19 will cost Rs 67,193 crore, of which states together will incur Rs 46,323 crore, India Ratings and Research (Ind-Ra) said on Thursday. As the second wave of COVID-19 sweeps the country with alarming speed and severity, the government has announced a liberalised and accelerated Phase 3 strategy of COVID-19 vaccination. Under this scheme, all persons above 18 years of age will be eligible to get COVID-19 vaccine doses from May 1.
The Subject Expert Committee on COVID-19 of the CDSCO on October 12 after deliberating Bharat Biotech's EUA application had recommended granting emergency use approval to Covaxin for use in the 12-18 years age group with certain conditions.
The vaccine maker Bharat Biotech said in a statement that preliminary reviews indicated that the death was unrelated to Covaxin.
865 million Indian adults require vaccination.
The vaccine candidate -- 'Covaxin' -- is being indigenously developed by the Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
'What the government should do is to use the vaccine judiciously, not just to prevent a third wave alone, but to stop the number of deaths happening in the interim.'
Even as the inoculation drive against COVID-19 is set to start in two days, a Maharashtra government official said on Thursday that it will take six to seven months for the vaccine to become available for those who are not in the high-risk category.
The Central Drugs Standard Control Organisation said while the rights, safety, and well-being of trial subjects were of paramount importance, protocol amendment, deviation or modification might be necessary in some cases owing to unavoidable circumstances.
The plan was activated in October last year.
There is confusion over the United Kingdom government's vaccine recognition process for Indian travellers as even though Oxford/AstraZeneca Covishield, the India-manufactured Oxford/AstraZeneca COVID-19 vaccine, is on an updated international travel advisory, India is not yet on a list of 17 approved countries.
During the webinar, 'COVID-19: Vaccination and Potential Return to Normalcy - If and When', Dr Hotez, an internationally-recognised physician-scientist in neglected tropical diseases and vaccine development, said that the COVID-19 vaccine rollout is "India's gift' to the world in combating the virus.
The Oxford vaccine, which also has a tie-up with the Serum Institute of India, was first administered to Brian Pinker, an 82-year-old Oxford-born dialysis patient. Pinker is among the first to be vaccinated by the Oxford University Hospital's (OUH) chief nurse, hailed as a major milestone in the phased vaccination programme being undertaken by the National Health Service (NHS).
If booster shots are given on priority, the pace of vaccination may slow further. In the worst case scenario, the country will take till mid-March to vaccinate its entire adult population partially.
'Scientifically the effect and change of Delta plus has to be watched through our INSACOG system. This has to be detected and we have to see its presence in the country'
Poonawalla said the price will be around USD 5-6 per dose with an MRP of around Rs 1,000 for the two necessary doses.
Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.
An alert government in Delhi should have begun government-to-government discussions with Moscow the moment it came to know that Russians were developing a vaccine. That is to say, almost an year's time has been lost, observes Ambassador M K Bhadrakumar.
As India prepares to launch its vaccine drive on January 16, here is a look at the options:
Health Minister Harsh Vardhan said the COVID-19 vaccine will be available in the next few months and it is estimated that by July-August 400-500 million doses will be made available for 25-30 crore people.
Bharat Biotech on Thursday said it plans to produce additional 200 million doses of COVID-19 vaccine 'Covaxin' at its subsidiary's Ankleshwar (Gujarat) based facility, taking the overall production volume of the vaccine to 1 billion (100 crore) dosages per annum.
Will syringe shortage puncture India's Covid vaccine plans?
The UK government is under increasing pressure on Monday to review its COVID-19 vaccine protocol in place for travellers from India, after its updated rules effective from next month failed to recognise Indian vaccines under an expanded list of countries.
This is the fifth consecutive day that COVID-19 cases have increased by more than 50,000 in the country.
The SC said journalists' work can be done without coming in contact with people unlike lawyers and asked the Centre to consider the legal fraternity's request for priority in COVID-19 vaccination saying their livelihood depends on direct interaction with their clients.
Procurement of coronavirus vaccines and raw materials to boost domestic production is set to be a major focus area of External Affairs Minister S Jaishankar's five-day visit to the United States beginning Monday.
The sale of the Lincoln House in the Breach Candy area of south Mumbai, which used to house the US consulate, to the billionaire chairman of the Pune-based Serum Institute, makes it the largest real estate deal in the country's financial capital.
India has airlifted more than 6 million COVID-19 doses to nine countries in Phase-I under its initiative termed "Vaccine Maitri".
In a report submitted Monday to Rajya Sabha chairman and Vice President M Venkaiah Naidu, the Parliamentary Standing Committee on Home Affairs also said there was a need for a comprehensive public health law to keep a tab on private hospitals and check black-marketing of medicines.
The government may look at areas around Thonnakkal, in Thiruvananthapuram district, for the facility. If successful, this would be one of the few sites of Sputnik V owned by Russian firms outside that country. Shine Jacob and Sohini Das report.
"The president pledged America's steadfast ongoing support for the people of India, who have been impacted by the recent surge in the COVID-19 cases," White House Press Secretary Jen Psaki told reporters at her daily news conference.
The Centre is looking to procure around 1 billion syringes between September and December to support the COVID-19 vaccination drive.
Responding to a question on the Rajasthan government's claim that there is a shortage in COVID-19 vaccine stock, Union Health Secretary Rajesh Bhushan said the central government regularly monitors the availability of vaccine supply in all states and UTs and their consumption on a daily basis.
The state also said that the police had recorded the statements of 400 witnesses so far and the investigators were in the process of finding the whereabouts of a doctor, who was an accused in the incident that took place at a housing society in suburban Kandivali, where one such camp was held.
They said 37.5 crore of Covishield doses from the Serum Institute of India and 28.5 crore Covaxin doses from Bharat Biotech will be procured by December.
Sources close to the development said the company had no further supply commitments to the WHO, and therefore, there was no suspension of any upcoming orders, reports Sohini Das.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances